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parameters (e.g. rate of HAQ progression and baseline demographics) and assump-
tions (e.g. extent to which HAQ improvement diminishes on withdrawal from ther-
apy) are influential on the ICER. CONCLUSIONS: Our results indicate that Adali-
mumab, and also Etanercept, have the highest probability of being the most cost-
effective of the biologic strategies at typical values of WTP.
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OBJECTIVES: Although osteoporosis is well recognized as a risk factor for fractures
among postmenopausal women, there has been no appraisal of the economic im-
pact of anti-osteoporotic therapy in Korea. Cost-effectiveness and cost-utility anal-
yses of anti-osteoporotic therapy were performed from the Korea National Health
Insurer perspective METHODS: Markov cohort simulation was performed to com-
pare the impact of bisphosphonates therapy to placebo in terms of incremental
cost per fracture averted and incremental cost per quality-adjusted life year (QALY)
saved for a hypothetical cohort of 1,000 Korean elderly osteoporotic women.
Within each health intervention strategy, all individuals began the simulation in
the health state ‘healthy’ and moved among the 5 health states (healthy, healthy
post-vertebral fracture, healthy post-hip fracture, healthy post 2nd hip fracture, and death)
in yearly cycles until 99 years old or death. To obtain transition probability of having
fractures, age-specific incidence rate of fracture was derived from published literature.
The combined weighted mean efficacy of alendronate and risedronate , which are the
most widely used bisphosphonates in Korea, for reducing the risk of fracture was
calculated from efficacy measures drawn from a meta-analysis. Data regarding
utilities and costs of fractures were derived from published local sources.RESULTS:
In the base case, the estimated incremental cost-utility ratio (ICUR) was 35 million
Korean won (KRW) per quality-adjusted life-year (QALY) gained, and the estimated
incremental cost-effectiveness ratio was 15 million KRW per fracture averted. Ac-
cording to the sensitivity analysis results, the efficacy of bisphosphonates therapy
and the starting age of therapy had the biggest impact on the estimated ICUR.
CONCLUSIONS: Based on this analysis, bisphosphonates therapy is likely to be
cost-effective for the primary prevention of fracture among Korean elderly women
at a willingness-to-pay threshold of 40-60 million KRW (i.e., 2-3 times per-capita
gross domestic product) per QALY.
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OBJECTIVES: To evaluate the cost per ACR70 response rate of biologic disease-
modifying antirheumatic drugs (bDMARDs) in the treatment of patients with active
rheumatoid arthritis (RA) and inadequate response to traditional DMARDs
(DMARD-IR) from the perspective of the Portuguese public health service.
METHODS: A systematic literature review considering randomized, controlled,
double-blind, multicentric clinical trials that evaluated the efficacy of bDMARDs’ -
abatacept, adalimumab, etanercept, golimumab, infliximab and tocilizumab – in
combination with DMARDs in the treatment of patients with active RA and
DMARD-IR, was performed, and 22 clinical trials were identified. ACR70 response
rates in each trial were adjusted for a placebo reference rate, which incorporated
the placebo response rates observed in all the trials. Odds ratio between the pla-
cebo group and the placebo reference group was thus assumed to reflect the base-
line differences between each trial results and a global reference population. Meta-
analyses were then performed to obtain the adjusted ACR70 response rate for each
bDMARD. The analysis considered drug and administration costs, obtained from
Portuguese official sources, and a 6-month time horizon. RESULTS: The highest
adjusted ACR70 response rate was obtained with tocilizumab (31,3%) followed by
adalimumab (25%), golimumab (20,2%), infliximab (19,6%), etanercept (15,5%) and
abatacept (11,7%), which is in line with earlier published evidence. Treatment costs
were lower with infliximab (4.577€) followed by tocilizumab (5.366€), etanercept
(5.695€), golimumab (5.921€), adalimumab (6104€) and abatacept (7.764€). The low-
est mean treatment cost to achieve an ACR70 response was obtained with tocili-
zumab (17.143€) followed by infliximab (23.354€), adalimumab (24.414€), goli-
mumab (29.311€), etanercept (36.743€) and abatacept (66.356€). CONCLUSIONS:
Due to the higher predicted ACR70 response rate, using tocilizumab for the treat-
ment of adult RA DMARD-IR patients provides the lowest cost per 70% or higher
improvement in disease activity among bDMARDs.
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Venous thromboembolism (VTE) is a disease that includes both deep vein throm-
bosis (DVT) and pulmonary embolism (PE), representing a serious public health
concern due to its impact in morbidity and mortality, and higher costs. Without
any prophylaxis, the incidence of DVT in patients undergoing total knee replace-
ment surgery (TKRS) ranges 40-84%. OBJECTIVES: To assess the cost and effective-
ness of bemiparin and enoxaparin when used as prophylaxis for VTE in TKRS under
the perspective of the Mexican public health care system. METHODS: We con-
ducted an economic evaluation based in a decision tree. Competing interventions
were bemiparin 3.500 IU/d started 6 hours after surgery and enoxaparin 40 mg/d
started 12 hours before surgery, for 102 days. Time horizon covered prophylaxis
plus 6 weeks of follow-up after hospital discharge. Probabilities of VTE events
(proximal DVT and symptomatic PE) as well as complications (major/minor bleed-
ing and thrombocytopenia) were derived from a head-to-head randomized double-
blind clinical trial. Only direct medical costs, comprising the acquisition cost of
agents used as prophylaxis besides the medical attention of VTE events and com-
plications, were analyzed. Resource use was determined by a Delphi Panel and
published literature. Unit costs were gathered from The Mexican Social Security
Institute (IMSS). Diagnosis-related groups’ costs at IMSS were also included into the
analysis. All costs are expressed in 2011 Mexican pesos (MXN). The efficacy mea-
sure was the proportion of patients free of VTE events. RESULTS: Selected VTE
events were 70% lower with bemiparin than with enoxaparin (18 vs. 60 cases per
1000 patients). Bemiparin also provided savings of 3521 MXN (47.4%) per patient
when used instead of enoxaparin for prophylaxis of VTE in TKRS. Model was
robust. CONCLUSIONS: Bemiparin is a dominant (both less costly and more effec-
tive) intervention over enoxaparin for the prophylaxis for VTE in TKRS in the Mex-
ican public health care setting.
PMS35
COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE TREATMENT OF ACTIVE
RHEUMATOID ARTHRITIS (RA) PATIENTS WITH INADEQUATE RESPONSE TO
ANTI-TNF TREATMENT IN TURKEY
Ertenli I
Hacettepe University Faculty of Medicine, Ankara, Turkey
OBJECTIVES: RA prevalence is 0.5% in Turkey. This rate, as those in other Medi-
terranean countries, is lower compared with other European countries,. Initial RA
treatment consists of using Disease Modifying Anti-Rheumatic Drugs (DMARDs).
Following inadequate response to DMARDs patients may switch to biologic treat-
ment options including tumour-necrosis factor (TNF) inhibitors. Tocilizumab is
approved by Turkish Ministry of Health for the treatment of active RA patients who
have responded inadequately to previous anti-TNF therapy. The study aimed to
assess tocilizumab’s cost-effectiveness for treatment of active RA patients with
inadequate response to previous anti-TNF treatment in Turkey. METHODS: Cost-
effectiveness analysis performed from payer’s perspective considered direct med-
ical costs. Markov model was used to compare two treatment sequences:1) tocili-
zumab, rituximab, abatacept, leflunomide, cyclosporin, palliative care, and 2)
rituximab, abatacept, leflunomide, cyclosporin, palliative care. Time horizon was
end of life. Patient characteristics were based on phase III study data (RADIATE).
Mixed treatment comparison was used to adjust ACR response rates for each of the
treatments in both sequences. Relationship between HAQ-DI scores and EuroQol
(EQ-5D) utilities was modeled by using patient data from trials. Resource use was
estimated based on expert opinion. Treatment costs (drug acquisition, administra-
tion, monitoring) were obtained from official lists published by Turkish Ministry of
Health and public payer. Costs and effects were not discounted. Results were tested
using deterministic and probabilistic sensitivity analyses. RESULTS: Treatment
sequence initiated with tocilizumab resulted in 0,528 life years gained and 1,873
QALYs more than alternative sequence at an additional cost of TRY63.788. ICER
was TRY34.052/QALY, which is below the threshold (TRY53.000/QALY based on
WHO recommendation). Sensitivity analyses confirmed that ICER was below the
threshold in 97% of the samples. CONCLUSIONS: Treatment initiated with tocili-
zumab in active RA patients with inadequate response to previous anti-TNF treat-
ment is cost-effective compared to alternative treatment sequence in Turkey.
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OBJECTIVES: To evaluate the cost-effectiveness of denosumab compared to alen-
dronate, zoledronic acid and no active osteoporosis treatment, for the treatment of
post-menopausal osteoporosis (PMO) in elderly women aged 75 years and older in
Sweden. METHODS: A previously developed Markov cohort model was updated
and used to estimate costs and effects, i.e. reductions in fracture occurrence, of
denosumab vs. comparators in that elderly population. The model was populated
with Swedish data on cost and fracture risks, and available clinical trial evidence
on treatment fracture risk reduction for hip, vertebral and other fractures in an
elderly population aged 75 years or older, where available. A life-time perspective
was applied and analysis were performed both with the assumption that all pa-
tients stay on therapy for all 5 years and that some patients drop out of treatment
over time (i.e. adjusting for imperfect treatment persistence). RESULTS: The base-
case analysis showed that denosumab was cost-saving and more effective (i.e.
dominant) versus all three comparators. The cost savings without adjustment for
imperfect treatment persistence amounted to €4,500, €4,800 and €500 per patient,
compared to no treatment, zoledronate and alendronate, respectively. Hip fracture
is the most common fracture type in the elderly population, and denosumab treat-
ment for 5 years avoided 140, 100 and 55 hip fractures per 1,000 treated patients,
compared to no treatment, zoledronate and alendronate, respectively. Univariate
and probabilistic sensitivity analyses showed that results were stable; denosumab
dominated all comparators if consequences of imperfect treatment persistence
were included or if comparator treatment costs were set to zero. CONCLUSIONS:
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Denosumab is a more cost-effective treatment alternative in an elderly PMO pop-
ulation. Compared to no treatment, zoledronic acid, and alendronate, denosumab
can improve care in elderly PMO patients above 75 years and at the same time
lower overall treatment costs in Sweden.
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OBJECTIVES: To determine the cost-effectiveness of biologic drugs for moderate to
severe psoriatic arthritis (PsA) using a 40-year German health care perspective.
METHODS: A network meta-analysis of 8 biologics RCTs determined short-term
efficacy using Psoriasis Area and Severity Index 75% (PASI75) and American College
of Rheumatology (ACR) responses and Health Assessment Questionnaire (HAQ)
and PASI improvements. Published evidence and assumptions were used to predict
long-term efficacy using a decision analytic model. Costs included drug acquisi-
tion, administration, monitoring, and hospitalisation. Incremental cost-effective-
ness ratios (ICERs) were calculated using Quality Adjusted Life Years (QALYs), func-
tion (HAQ-adjusted life years), and years in PASI75 response. RESULTS: For the
QALY analysis, golimumab was extended dominated by adalimumab. The incre-
mental costs and QALYs for adalimumab vs. palliative care were €32046 and 0.671,
producing an ICER of €47728/QALY. Etanercept was estimated to provide margin-
ally more QALYs (0.060) at an additional €3461 (ICER of €57380/QALY vs. adali-
mumab). Although infliximab was estimated to give the most QALYs (0.031 more
than etanercept), the cost was an additional €8046 (ICER for infliximab of €260940/
QALY vs. etanercept). Results for the HAQ-adjusted life year analysis were similar,
where adalimumab (€293/HAQ life year) had similar results in comparison to etan-
ercept (€292/HAQ life year). For years in PASI75 response, etanercept became dom-
inated, golimumab gave 2.308 incremental PASI75 life years at an incremental cost
of €29463 (ICER of €12765/PASI75 life year vs. palliative care), adalimumab gave
2.704 incremental PASI75 life years at an incremental cost of €32064 (ICER of €11851/
PASI75 life year vs. palliative care), and infliximab became the optimal strategy
with 4.407 incremental QALYS at an additional €43553 (ICER of €9883/PASI75 life
year vs. palliative care). CONCLUSIONS:Using QALYs, which combine the skin and
joint aspects of disease, adalimumab and etanercept were the most cost-effective
biologic strategies; infliximab gave marginally more benefit at a much higher cost.
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OBJECTIVES: To assess the cost-effectiveness of tapentadol prolonged release
compared to morphine, oxycodone, hydromorphone, transdermal buprenorphine
[TDB], and transdermal fentanyl [TDF] for the treatment of severe chronic non-
cancer pain in Belgium. METHODS: A one year Markov transition state model with
4-week cycles was built. Four health states were defined: ‘no withdrawal and no
adverse events treated’, ’occurrence of adverse events (AEs) with need for medical
treatment’, ’withdrawal due to AEs’, and ‘withdrawal due to lack of efficacy’. Pa-
tients who were lacking efficacy or had poor tolerability switched to an alternative
2nd line opioid (oxycodone, morphine, hydromorphone, TDB or TDF). 3rd line ther-
apy was the absorbing state. Data regarding efficacy, tolerability and utility values
(EQ-5D) were derived from clinical trials and published literature. Switch rates to
2nd line therapies and resource consumption were estimated by clinical experts.
Costs were calculated from the health care payer perspective including patients’
co-payments as stated in the Belgium pharmacoeconomic guidelines. One-way,
scenario, and probabilistic sensitivity analyses were conducted. RESULTS: Com-
pared to oxycodone (direct comparison data), tapentadol had almost the same cost
but higher effectiveness, resulting in the incremental cost-effectiveness ratio
(ICER) of 6 EUR per QALY gained. The ICERs of tapentadol versus TDB, TDF, hydro-
morphone and morphine equaled to 2,407, 5,811, 19,852, and 23,182 EUR per QALY
gained, respectively. In the univariate sensitivity analysis, resource consumption,
probabilities and utilities were varied for 50%, 20% and 10%, respectively.
Conclusions about the cost-effectiveness of tapentadol remained robust, especially
when compared to oxycodone, TDF and TDB, which account for ca. 90% of the total
strong opioid market in Belgium. The ICER in these cases did not exceed 10,000 EUR
per QALY gained. CONCLUSIONS: To improve pain relief and quality of life in
patients with severe chronic pain tapentadol appears to be the favourable and
cost-effective treatment option in Belgium.
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OBJECTIVES: Currently, anti-TNF monoclonal antibodies are the mainstay of
therapy in patients with active rheumatoid arthritis (RA) and inadequate response
to methotrexate (MTX) alone. The purpose of this analysis is to evaluate the cost-
effectiveness of certolizumab pegol (CZP) versus other anti-TNF (adalimum-
ab[ADA], infliximab [INF] and etanercept [ETA]) as adjunctive therapy to MTX from
the perspective of the Brazilian private health care system. METHODS: Cost-effec-
tiveness for 52 weeks of treatment was evaluated based on the ACR20 response rate
at week 24 based on main published RCTs for each anti- TNF. An indirect compar-
ison was performed using Glenny et al method1. Annual drug costs for each aTNF
were calculated from their published ex-factory prices and their recommended
dosing schedule in the Brazilian product information. For the calculation of the
annual INF cost, the initial weight of the patient assumed for the model was as-
sumed to be 65Kg, with no increment of the doses after 22 weeks. Results are
presented in USD (June 11th, 2012 exchange rate) annual costs and incremental
cost-effectiveness ratios (ICER’s). A sensitivity analysis was made on price discount
rate. RESULTS: Annual costs were estimated in USD $12,619, USD $39,305, USD
$24,267 and USD $35,617 for CZP, ADA, INF and ETA, respectively. Adjusted by
indirect comparison of ACR20 response were 77% for CZP and 67%, 61% and 45%
for ADA, INF and ETA, respectively. The cost effective ratio was USD $16,484 for
CZP and USD $79,742, USD $59,326, USD $40,299 for ETA, ADA and INF respec-
tively. The cost-effectiveness analysis demonstrated that CZP was a dominant
strategy compared with ADA, INF and ETA. CONCLUSIONS: Certolizumab pegol
(CZP) is a cost- saving anti-TNF option for treating RA from a Brazilian private
health care perspective.
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OBJECTIVES: Cost-effectiveness of denosumab versus other treatments in MOP in
 75-year-olds in Sweden was evaluated from a third-party payer perspective.
METHODS: A lifetime cohort Markov model was developed with seven health
states: well, hip fracture, vertebral fracture, other osteoporotic fracture, post hip
fracture, post vertebral fracture, and dead. During each cycle, patients could have
a fracture, remain healthy, remain in a post fracture state or die. Background frac-
ture risks, mortality rates, persistence rates, utilities, medical and drug costs were
derived using published sources. BMD improvements have been shown to be sim-
ilar across MOP and post-menopausal osteoporotic (PMO) populations; therefore in
the absence of well-powered trials evaluating fracture risk reduction in MOP, effi-
cacy was obtained from studies in PMO women. Lifetime expected costs and qual-
ity-adjusted life-years (QALYs) were estimated for denosumab, generic alendro-
nate, generic risedronate, ibandronate, zoledronate, strontium ranelate and
teriparatide. On average, patients in the model were 78 year-old men, with bone
mineral density T-score-2.12 and prevalent vertebral fracture of 23%. In the base-
case, the model assumed patients could receive treatment effects up to 5 years
after discontinuation, except on teriparatide (only 2 years). Costs and QALYs were
discounted at 3% annually. Extensive sensitivity analyses were conducted.
RESULTS: Total lifetime costs for denosumab, alendronate, zoledronate, strontium
ranelate, risedronate, ibandronate and teriparatide were €31,324, €34,834, €35,592,
€35,939, €36,008, €37,211 and €38,632, respectively. Total QALYs were 5.22, 5.12,
5.15, 5.12, 5.11, 5.09 and 5.19, respectively. Denosumab dominated all treatments by
having lower costs and higher QALYs. Denosumab dominated generic alendronate
(next least expensive strategy) in the one-way sensitivity analyses also. The prob-
ability of denosumab being cost-effective compared to the other treatments at a
threshold of €66,000/QALY was 99.0%. CONCLUSIONS: Denosumab dominated al-
most all comparators, including generic bisphosphonates in the Swedish MOP pop-
ulation  75 years-old.
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OBJECTIVES: To assess the cost-effectiveness of denosumab and zoledronate in
preventing fractures related to osteoporosis in postmenopausal women from the
private health care sector perspective in Brazil. METHODS: A previously validated
Markov model comprising eight health states (no fracture, hip, vertebral, wrist and
other osteoporotic fractures, post hip and post vertebral fractures, and death)
quantified lifetime costs and benefits within six-month intervals. Analyzed popu-
lation consisted of postmenopausal women 72 years. Age-related risk fracture
was modeled and fracture-specific risk reductions of each targeted therapy were
computed. Efficacy data were derived from published randomized clinical trials.
The analysis included direct costs using ex-factory drug prices. Medical and labo-
ratory costs came from the Brazilian Medical Association reimbursement list. Frac-
ture-related (i.e., hospitalization, surgery) and follow-up (i.e., rehabilitation) costs
were extracted from a private health care database (BI2im). Costs were reported in
2012 Brazilian currency (1BRL0.52USD). Outcomes assessed were 10-year fracture
event incidence and quality-adjusted life years (QALYs). Costs and benefits were
discounted 5% yearly. Univariate and multivariate (probabilistic) sensitivity anal-
yses tested model robustness. RESULTS: Average morbidity costs were BRL2,722
and BRL2,839 for denosumab and zoledronate, respectively. Intervention costs
were BRL5,153 for denosumab and BRL5,481 for zoledronate. Lifetime cost differ-
ence between alternatives was BRL446 per patient treated. Ten-year fracture inci-
dence was lower with denosumab: reductions of 0.5% and 1.5% for hip and verte-
bral fractures, respectively, over zoledronate. Average QALYs were 6.861 and 6.841
for denosumab and zoledronate. Denosumab reduced fracture incidence and im-
proved QALYs at a lower cost. Denosumab remained cost-efffective after changes
in individual model parameters (up to 20% variability), considering a willingness-
to-pay of BRL57,000/QALY gained (3x Brazilian GDP/capita). Multivariate sensitivity
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